ANDROGEN RECEPTOR IN TRIPLE NEGATIVE BREAST CANCER
Though many recent developments have been provided in terms of breast cancer treatments and targeted therapy, the incidence of breast cancer is increasing throughout the world and it is the leading cause of cancer death in females. The most heterogeneous type of breast cancer is the triple negative breast cancer (TNBC), involving many subtypes and mixed entities which differ in many aspects: histology, molecular markers, prognosis, treatment and patient outcomes. Triple negative breast cancer is also the most aggressive type of breast cancer due to its lack of hormone receptors and HER2 amplification. Recent studies have demonstrated the implication of androgen receptor (AR) in prognosis and therapy of TNBC although this has not yet been completely elucidated. The aim of this review is to provide an overview about TNBC and to state androgen receptor role and its importance in therapy of breast cancer in the near future.